特比萘芬临床应用专家共识

摘要/Abstract

中图分类号:

R978.5

特比萘芬临床应用专家共识工作组. 特比萘芬临床应用专家共识[J]. 中国真菌学杂志, 2020, 15(5): 257-261.

Expert group of consensus on the clinical application of Terbinafine. Clinical Application of Terbinafine：Expert consensus[J]. Chinese Journal of Mycology, 2020, 15(5): 257-261.

参考文献 55

[1]	Elewski BE. Mechanisms of action of systemic antifungal agents[J]. J Am Acad Dermatol, 1993,28(5 part 1):S28-S34.
[2]	Finlay AY. Global overview of lamisil[J]. Br J Dermatol,1994,130(Suppl 43):1-3.
[3]	Finlay AY. Pharmacokinetics of terbinafine in the nail[J]. Br J Dermatol, 1992,126(Suppl 39):28-32.
[4]	Zehender H, Cabiac MD, Denouël J, et al. Elimination kinetics of terbinafine from human plasma and tissues following multiple-dose administration, and comparison with 3 main metabolites[J]. Drug Invest,1994,8(4):203-210.
[5]	Balfour JA, Faulds D.Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses[J].Drugs, 1992,43(2):259-284.
[6]	陈铁锋,余细勇,林曙光,等.盐酸特比萘芬凝胶的透皮吸收[J].中国现代应用药学,2004,21(S2):48-50.
[7]	Ryder NS. Terbinafine:mode of action and properties of the squalene epoxidase inhibition[J]. Br J Dermatol, 1992,126(Suppl 39):2-7.
[8]	Roberts DT.Oral terbinafine (lamisil) in the treatment of fungal infections of the skin and nails[J]. Dermatology, 1997,194(Suppl 1):37-39.
[9]	Petranyi G, Meingassner JG, Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro[J]. Antimicrob Agents Chemother, 1987,31(9):1365-1368.
[10]	燕华玲,王爱平,万喆,等.特比萘芬对白念珠菌菌丝相和酵母相敏感性的比较[J].中华皮肤科杂志,2005,38(8):515.
[11]	Goodfield MJD, Andrew L, Evans EGV. Short term treatment of dermatophyte onychomycosis with terbinafine[J]. BMJ, 1992,304:1151-1154.
[12]	van der Schroeff JG, Cirkel PKS, Crijns MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis[J]. Br J Dermatol,1992,126(Suppl 39):36-39.
[13]	Baudraz-Rosselet F, Rakosi T, Wili PB, et al. Treatment of onychomycosis with terbinafine[J]. Br J Dermatol, 1992,126(Suppl 39):40-46.
[14]	McClellan KJ, Wiseman LR,Markham A. Terbinafine:An update of its use in superficial mycoses[J]. Drugs, 1999,58(1):179-202.
[15]	Gupta AK, Gover MD, Lynde CW. Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus[J]. J Eur Acad Dermatol Venereol, 2006, 20(10):1188-1193.
[16]	Nandwani R, Parnell A, Youle M, et al.Use of terbinafine in HIV-positive subjects:pilot studies in onychomycosis and oral candidiasis[J]. Br J Dermatol, 1996,134(Suppl 46):22-24:discussion 39.
[17]	Gupta AK, Lynch LE, Kogan N,et al. The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis[J]. J Eur Acad Dermatol Venereol, 2009, 23(3):256-262.
[18]	Gupta AK, Sibbald RG, AndriessenA,et al.Toenail onychomycosis-a Canadian approach with a new transungual treatment:development of a clinical pathway[J]. J Cutan Med Surg, 2015, 19(5):440-449.
[19]	Carrillo-Muñoz AJ, Giusiano G, Cárdenes D, et al.Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis[J]. Int J Antimicrob Agents, 2008,31(6):540-543.
[20]	Ranawaka RR, Nagahawatte A, Gunasekara TA,et al.Randomized, double-blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis:A study with 90 patients[J]. J Dermatolog Treat, 2016,27(4):364-372.
[21]	Evans EGV. Resistance of Candida species to antifungal agents used in the treatment of onychomycosis:a review of current problems[J]. Br J Dermatol, 1999,141(Suppl 56):33-35.
[22]	中国头癣诊疗指南工作组.中国头癣诊断和治疗指南(2018修订版)[J].中国真菌学杂志,2019,14(1):4-6.
[23]	Drago L, Micali G, Papini M, et al. Management of mycoses in daily practice[J].G Ital Dermatol Venereol, 2017, 152(6):642-650.
[24]	Kakourou T, Uksal U, European Society for Pediatric Dermatology.Guidelines for the management of tinea capitis in children[J]. Pediatr Dermatol, 2010,27(3):226-228.
[25]	Haroon TS, Hussain I, Mahmood A, etal. An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis[J]. Br J Dennatol, 1992,126(Suppl 39):47-50.
[26]	Leung AKC, Hon KL, Leong KF,et al.Tinea capitis:An updated review[J].Recent Pat Inflamm Allergy Drug Discov, 2020,14(1):58-68.
[27]	Gupta AK, Mays RR, Versteeg SG,et al. Tinea capitis in children:a systematic review of management[J]. J Eur Acad Dermatol Venereol, 2018, 32(12):2264-2274.
[28]	Chen X, Jiang X, Yang M,et al.Systemic antifungal therapy for tinea capitis in children[J]. Cochrane Database Syst Rev, 2016,(5):CD004685.
[29]	Shwayder T.Terbinafine[J]. J Am Acad Dermatol, 1998,39(1):136.
[30]	中国体癣和股癣诊疗指南工作组.中国体癣和股癣诊疗指南(2018修订版)[J].中国真菌学杂志,2019,14(1):1-3.
[31]	中国中西医结合学会皮肤性病专业委员会真菌学组,中国医师协会皮肤科分会真菌亚专业委员会,中华医学会皮肤病分会真菌学组.手癣和足癣诊疗指南(2017修订版)[J].中国真菌学杂志,2017,12(6):321-324.
[32]	Shi TW, Zhang JA, Zhang XW, et al.Combination treatment of oral terbinafine with topical terbinafine and 10% urea ointment in hyperkeratotic type tinea pedis[J]. Mycoses, 2014,57(9):560-564.
[33]	Balfour JA, Faulds D.Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses[J].Drugs, 1992,43(2):259-284.
[34]	刘耕,于波.盐酸特比萘芬阴道泡腾片治疗念珠菌性阴道炎疗效观察[J].中国真菌学杂志,2006,1(6):41-42.
[35]	秦晓华,王明贵,Kanafani ZA,等.抗真菌药物的耐药机制及其临床意义[J]. 中国感染与化疗杂志,2010,10(4):320.
[36]	38-Rex JH, Pfaller MA.Has antifungal susceptibility testing come of age[J]? Clin Infect Dis, 2002, 35(8):982-989.
[37]	Guanziroli E, Pavia G, Guttadauro A, et al. Deep dermatophytosis caused by Trichophyton verrucosum in an immunosuppressed patient:successful outcome with terbinafine[J]. Mycopathologia, 2019, 184(4):543-545.
[38]	Boral H, Durdu M, Ilkit M. Majocchi's granuloma:current perspectives[J]. Infect Drug Resist, 2018,11:751-760.
[39]	Wang X, Yang Y, Li R, et al. Two cases of dermatophytic granuloma successfully treated with terbinafine[J]. Mycopathologia, 2018, 183(3):611-614.
[40]	Zhou S, Yang Y, Liu K, et al. A case report of widespread Majocchi's granuloma in a patient with systemic lupus erythematosus[J]. Mycopathologia, 2017, 182(5-6):577-581.
[41]	Mahajan VK.Sporotrichosis:an overview and therapeutic options[J]. Dermatol Res Pract, 2014, 2014:272376.
[42]	中华医学会皮肤性病学分会真菌学组,中国医师协会皮肤科医师分会医学真菌亚专业委员会,中西医结合学会皮肤性病专业委员会真菌学组. 孢子丝菌病诊疗指南[J]. 中华皮肤科杂志,2016, 49(7):456-459.
[43]	Francesconi G, Valle AC, Passos S, et al.Terbinafine (250 mg/day):an effective and, safe treatment of cutaneous sporotrichosis[J]. J Eur Acad Dermatol Venereol, 2009, 23(11):1273-1276.
[44]	Francesconi G, Francesconi do Valle AC, Passos SL, et al. Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis[J]. Mycopathologia, 2011, 171(5):349-354.
[45]	Chapman SW, Pappas P, Kauffmann C,et al.Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(-1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis[J]. Mycoses, 2004, 47(1-2):62-68.
[46]	Hull PR, Vismer HF. Treatment of cutaneous sporotrichosis with terbinafine[J]. Br J Dermatol, 1992, 126(Suppl 39):51-55.
[47]	Queiroz-Telles F, de Hoog S, Santos DW, et al. Chromoblastomycosis[J]. Clin Microbiol Rev, 2017,30(1):233-276.
[48]	Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation:Part II Lactation[J]. J Am Acad Dermatol, 2014, 70(3):417.e1-10; quiz 427.
[49]	Wang Y, Lipner SR. Retrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug Administration[J].J Dermatolog Treat,2020:1-5.
[50]	Stolmeier DA, Stratman HB, McIntee TJ,et al. Utility of laboratory test result monitoring in patients taking oral terbinafine or griseofulvin for dermatophyte infections[J]. JAMA Dermatol, 2018, 154(12):1409-1416.
[51]	Patel D,Castelo-Soccio LA, Rubin AI,et al. Laboratory monitoring during systemic terbinafine therapy for pediatric onychomycosis[J]. JAMA Dermatol, 2017,153(12):1326-1327.
[52]	García Rodríguez LA, Duque A, Castellsague J, et al. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs[J]. Br J Clin Pharmacol, 1999,48(6):847-852.
[53]	Kantarc?o?lu B, Türköz HK, Y?lmaz G, et al. Aplastic anemia associated with oral terbinafine:a case report and review of the literature[J]. Turk J Haematol, 2014,31(4):411-416.
[54]	Gupta AK, Soori GS, Del Rosso JQ, et al. Severe neutropenia associated with oral terbinafine therapy[J]. J Am Acad Dermatol, 1998,38(5 Pt 1):765-767.
[55]	Vickers AE, Sinclair JR, Zollinger M, et al. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions[J]. Drug Metab Dispos,1999,27(9):1029-1038.

特比萘芬临床应用专家共识

Clinical Application of Terbinafine：Expert consensus

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 55

相关文章 15

编辑推荐

Metrics

本文评价

[1]	中国手癣和足癣诊疗指南工作组. 中国手癣和足癣诊疗指南(基层实践版2020)[J]. 中国真菌学杂志, 2020, 15(6): 325-330.
[2]	季梅, 隗祎. 儿童脓癣2例[J]. 中国真菌学杂志, 2020, 15(6): 366-367,377.
[3]	朱红梅, 温海. 特比萘芬在皮下及深部真菌感染中的临床应用[J]. 中国真菌学杂志, 2020, 15(6): 374-377.
[4]	王玲, 景东云, 王学军, 刘俊, 曹月清. 长脉宽Nd:YAG 1064 nm激光治疗远端侧位甲下型甲真菌病的疗效观察及对真菌超微结构的影响[J]. 中国真菌学杂志, 2020, 15(5): 268-273.
[5]	朱红梅, 温海. 特比萘芬在浅表真菌感染中的临床应用[J]. 中国真菌学杂志, 2020, 15(5): 297-303.
[6]	李敬波, 徐宇, 张芙蓉. Majocchi肉芽肿研究进展[J]. 中国真菌学杂志, 2020, 15(5): 306-309.
[7]	步青云, 王润超, 罗亭, 卢昌佩, 景海霞. 甲真菌病的激光治疗新进展[J]. 中国真菌学杂志, 2020, 15(5): 310-313.
[8]	梁官钊, 刘维达. 球孢子菌病的临床特征及诊治策略[J]. 中国真菌学杂志, 2020, 15(5): 314-317.
[9]	闫玮, 符美华, 梅嬛, 陈伟, 刘维达. 土曲霉致耳真菌病1例并文献复习[J]. 中国真菌学杂志, 2020, 15(4): 233-235.
[10]	朱红梅, 温海. 特比萘芬耐药皮肤癣菌的研究进展[J]. 中国真菌学杂志, 2020, 15(4): 253-256.
[11]	徐瑾, 何咏, 黄玲珍, 胡云峰, 吴实, 刘赛君, 邓列华. 荧光染色法、双重荧光染色法与KOH湿片法在甲真菌诊断中的比较研究[J]. 中国真菌学杂志, 2020, 15(3): 167-169,172.
[12]	余进, 刘伟, 陈伟, 张晓梅, 万喆, 王爱平, 李若瑜. 关于重症新型冠状病毒肺炎继发侵袭性真菌感染实验室诊治建议[J]. 中国真菌学杂志, 2020, 15(1): 1-5.
[13]	付洁, 吴斌. 萘替芬酮康唑乳膏治疗皮肤真菌病安全性与有效性的meta分析[J]. 中国真菌学杂志, 2019, 14(5): 270-276.
[14]	熊瑛, 陈婷, 柴宝, 曾飞鹏, 孙文文, 吴波. 不同激光不同能量对红色毛癣菌的体外抑制评估及部分机制的探讨[J]. 中国真菌学杂志, 2019, 14(5): 292-296.
[15]	朱红梅, 温海, 李斌. 外用抗真菌中草药的研究进展[J]. 中国真菌学杂志, 2019, 14(5): 316-320.